...Documented KRASG12C mutation, based on tissue analysis on either archived tissue or new biopsy before inclusion, and verified locally by a validated method. ...

...- Subject has provided informed consent prior to initiation of any study specific activities/procedures.- Age >= 18 years.- Pathologically documented, locally-advanced, and unresectable or metastatic non-small cell lung cancer.- Have documentation of KRAS p.G12C mutation per local testing guidelines or a screening for another Amgen sotorasib study.- Subject has exhausted other standard of care options for locally advanced and unresectable or metastatic disease including platinum-based combination chemotherapy, PD-1/PD-L1 immunotherapy, and docetaxel (unless contraindicated).- Eastern Cooperative Oncology Group (ECOG) performance status = 18 anni- Carcinoma polmonare non a piccole cellule patologicamente documentato, localmente avanzato e non resecabile o metastatico- Mutazione per KRAS p.G12C documentata secondo le linee guida dei test locali o al momento dello screening per altri studi Amgen con sotorasib- I soggetti non hanno più opzioni terapeutiche tra gli standard of care per malattia localmente avanzata e non resecabile o metastatica inclusa chemioterapia di combinazione a base di platino, immunoterapia PD-1/PD-L1 e docetaxel (a meno che non sia controindicato)- Performance status dell'Eastern Cooperative Oncology Group (ECOG) otocollo per la lista completa`- Subject has provided informed consent prior to initiation of any study specific activities/procedures.- Age ≥ 18 years.- Pathologically documented, locally-advanced, and unresectable or metastatic non-small cell lung cancer.- Have documentation of KRAS p.G12C mutation per local testing guidelines or a screening for another Amgen sotorasib study.- Subject has exhausted other standard of care options for locally advanced and unresectable or metastatic disease including platinum-based combination chemotherapy, PD-1/PD-L1 immunotherapy, and docetaxel (unless contraindicated).- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 - Adequate hematologic and end-organ function, defined as the following: - Absolute neutrophil count (ANC) > 1000 cells/μl (without granulocyte colony-stimulating factor support within 2 weeks of laboratory test used to determine eligibility) - Hemoglobin ≥ 9.0 g/dL - Platelet count ≥ 75 000/μL - AST and ALT < 2.5 x the upper limit of normal (ULN) (if liver metastases are present, ≤ 5 x ULN) - Total bilirubin < 1.5 x ULN (subjects with known Gilbert’s disease with serum bilirubin < 3 x ULN may be enrolled if direct bilirubin is < 1 x ULN and approved by Amgen Medical Monitor) - International normalized ratio (INR) or activated partial thromboplastin time (aPTT) < 1.5 x ULN - Serum creatinine ≤ 1.5 x ULN OR estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m2. ...

...Biomarker eligibility for S1900E is based on the identification of a KRAS^G12C mutation...

...- Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing performed according to in-country requirements....

...- Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing....

...Identification of a KRAS p.G12C mutation in tumor tissue or plasma by an approved diagnostic device for detection of KRAS p.G12C in NSCLC or through any nucleic acid-based diagnostic testing method [including droplet-digital PCR, real-time PCR based methods such as the Idylla KRAS Mutation Assay (Biocartis), tissue and circulating tumor DNA -based next generation sequencing, Sanger-sequencing etc] performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited laboratory....

...- Pathologically documented, previously treated, locally-advanced and unresectable or metastatic NSCLC with KRAS p.G12C mutation confirmed through central testing or have documentation of KRAS p.G12C mutation through Amgen Study 20190294 prior to enrollment...

...- Patients must have histologically documented, locally advanced and unresectable, or metastatic solid tumor with documentation of a KRAS-G12C mutation within 2 years prior to screening....

...- Documented KRASG12C mutation, based on tissue analysis on either archived tissue or new biopsy before inclusion, and verified locally by a validated method....

...- Pathologically documented metastatic NSCLC with KRAS G12C mutation (local confirmation)...

...- Presence of KRAS G12C mutation diagnosed on tumor sample and/or on liquid biopsy (co mutations allowed)...

...- Pathologically documented, locally-advanced and unresectable or metastatic Non Small-Cell Lung Cancer (NSCLC) with KRAS p.G12C mutation confirmed through molecular testing...

...Patients must have non-squamous NSCLC with KRAS G12C mutation identified through molecular testing (local assessment), AJCC 8 stages Ib, IIa, IIb, IIIa (single nodal station) and assessment by a thoracic surgeon that the patient is potentially resectable and physiologically operable....

...- Pathologically documented, previously treated, locally-advanced and unresectable or metastatic NSCLC with KRAS p.G12C mutation confirmed through molecular testing (results of both tissue and liquid biopsy are accepted);...

...have documentation of KRAS p.G12C mutation confirmed by local testing through the current protocol or have documentation of KRAS p.G12C mutation prior to enrollment....

...Advanced NSCLC with KRAS G12C mutationsii. ...

...Presence of KRAS G12C mutation in tumour tissue ...

...Pathologically documented, metastatic NSCLC with KRAS p.G12C mutation identified through molecular testing. ...

...For the full list of inclusion criteria please refer to section 5.1 of the of the subprotocols.All subprotocolsMeasurable disease per RECIST 1.1 criteria Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2Life expectancy of > 3 months, in the opinion of the investigatorAbility to take oral medications and willing to record daily adherence to investigational productCorrected QT interval (QTc) ≤ 470 msec for women and ≤ 450 msec for men (based on average of screening triplicatesAdequate hematological laboratory assessments, as follows:•Absolute neutrophil count (ANC) ≥ 1.5 x 109/L•Platelet count ≥ 100 x 109/L•Hemoglobin ≥ 9 g/dLAdequate renal laboratory assessments, as follows:•Estimated glomerular filtration rate based on Modification of Diet in Renal Disease (MDRD) calculation ≥ 60 ml/min/1.73 m2•Adequate coagulation laboratory assessments as follows: •PT or PTT or activated partial thromboplastin time ≤ 1.5 x ULN, OR (INR) ≤ 1.5 x ULN or within target range if on prophylactic anticoagulation therapy.Subprotocol F •Pathologically documented, locally-advanced or metastatic NSCLC with KRAS p.G12C mutation identified through molecular testing. ...

...- Age ≥ 18 years;- ECOG ≤ 1 at the time of screening;- Pathologically documented, previously treated, locally-advanced and unresectable or metastatic NSCLC with KRAS p.G12C mutation confirmed through molecular testing (results of both tissue and liquid biopsy are accepted);- Subjects will have progressed or experienced disease recurrence on or after receiving at least 1 prior systemic therapy for locally advanced and unresectable or metastatic disease. ...

The PFS benefit of intercalated use of gefitinib over placebo was more apparent for patients with EGFR-mutant tumors (13.3 vs. 7.8 months, P = .025) than those with EGFR-wild-type tumors (8.2 vs. 6.6 months, P = .063). Overall, there was no difference in the frequency of severe adverse effect between the 2 arms...The KRAS G12C mutation is a biomarker of poor prognosis in Chinese NSCLC patients, which could potentially be improved by G12C-specific inhibitors in the future.(296 words).